一例复发骨髓瘤患者中伊沙佐米诱发皮肤坏死性血管炎的罕见病例。
A Rare Case of Ixazomib-Induced Cutaneous Necrotizing Vasculitis in a Patient with Relapsed Myeloma.
作者信息
Katz Heather, Shenouda Mina, Dahshan Deena, Sonnier George, Lebowicz Yehuda
机构信息
Department of Hematology/Oncology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 500 Hofstra Blvd, Hempstead, NY 11549, USA.
Department of Hematology/Oncology, Joan C. Edwards School of Medicine, Marshall University, 1600 Medical Center Dr., Huntington, WV 25701, USA.
出版信息
Case Rep Hematol. 2019 Oct 20;2019:6061484. doi: 10.1155/2019/6061484. eCollection 2019.
Ixazomib is the only oral proteasome inhibitor used in relapsed/refractory myeloma. Cutaneous side effects due to ixazomib have been documented in the literature; however, cutaneous necrotizing vasculitis is extremely rare. We describe a case of a 74-year-old man with relapsed multiple myeloma who was started on ixazomib, lenalidomide, and dexamethasone. He developed several skin lesions that were biopsied and revealed cutaneous necrotizing vasculitis. Ixazomib was held with resolution of the vasculitic lesions and restarted with dexamethasone to 20 mg on the day of treatment and 20 mg dose the day after treatment.
伊沙佐米是唯一用于复发/难治性骨髓瘤的口服蛋白酶体抑制剂。文献中已记载了伊沙佐米引起的皮肤副作用；然而，皮肤坏死性血管炎极为罕见。我们描述了一例74岁复发多发性骨髓瘤男性患者，他开始使用伊沙佐米、来那度胺和地塞米松治疗。他出现了多处皮肤病变，经活检显示为皮肤坏死性血管炎。停用伊沙佐米后血管炎性病变消退，在治疗当天重新开始使用地塞米松，剂量为20毫克，治疗后一天剂量为20毫克。
Zotero 插件